Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046050 in Advanced Solid Tumors
NCT06131840Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Nov 2023
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 10
01
Overview
Phase 1, open-label trial of PF-08046050 in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), gastric cancer (GC) and 3 more (6 arms), sponsored by Pfizer. Primary endpoints: Adverse Events, Laboratory Abnormalities and 2 more. Started Nov 2023; status: recruiting.
02
Drugs
PF-08046050
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)gastric cancer (GC)pancreatic ductal adenocarcinoma (PDAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06131840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06131840.